You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 255 No. 2, January 10, 1986 TABLE OF CONTENTS
  JAMA
  •  Online Features
  CLINICAL CARDIOLOGY
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (11)
 •Contact me when this article is cited
 Related Content
 •Similar articles in JAMA
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Thrombolysis With Tissue-Type Plasminogen Activator in Acute Myocardial Infarction

Potentials and Pitfalls

Allan S. Jaffe, MD; Burton E. Sobel, MD

JAMA. 1986;255(2):237-239.

Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

RAPID dissemination of preliminary results of research may predispose the medical profession and the public to premature, ill-advised, or indiscriminate acceptance of allegedly therapeutic modalities before efficacy has been established. Objective evaluation of an intervention such as coronary thrombolysis may be obscured by excessive enthusiasm of advocates, undue cynicism of critics, media hype, and real or imagined competitive pressures impinging on the modern practitioner of medicine. In this article we shall consider, in this context, findings pertinent to coronary thrombolysis with conventional activators or tissue-type plasminogen activator (t-PA) in the treatment of acute myocardial infarction.

The concept that acute coronary thrombosis is responsible for myocardial infarction is not new. Initial attempts in 1959 by Sherry and associates were made to activate the fibrinolytic system in pilot studies of patients with acute infarction. Subsequently, 13 large-scale trials with intravenous streptokinase were performed in Europe and Scandinavia. Conflicting results ensued, in part . . . [Full Text PDF of this Article]


Author Affiliations

From the Cardiovascular Division, Washington University School of Medicine, St Louis.


Footnotes

This article is one of a series sponsored by the American Heart Association.

Reprint requests to Washington University School of Medicine, 660 S Euclid, Box 8086, St Louis, MO 63110 (Dr Sobel).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1986 American Medical Association. All Rights Reserved.